Status:
COMPLETED
Accurate Diagnosis of Multiple Sclerosis Using PET/MR
Lead Sponsor:
Ruijin Hospital
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Multiple sclerosis (MS) is an immune-mediated chronic inflammatory demyelinating disease of the central nervous system. Its main feature is progressive demyelination, which ultimately leads to axon da...
Eligibility Criteria
Inclusion
- MS Patients Group:
- between 18-65 years old;
- diagnosed with mild or moderate disease (EDSS score ≤ 5 points); it meets the 2017 new version of McDonald diagnostic criteria for multiple sclerosis.
- meet the diagnostic criteria of clinically isolated syndromes (CIS)
Exclusion
- No brain surgery/no brain trauma/no history of brain disease (stroke), no other independent neurological or psychiatric history;
- No severe depression symptoms;
- No alcoholism or drug dependence (addiction);
- No other conditions that affect the smooth progress of the inspection: such as hearing impairment, comprehension impairment, poor compliance, etc.;
- No rheumatic diseases and other acute or chronic inflammations (required for hematological markers).
- No MR contrast agent allergy
- Healthy Volunteers Group:
- Inclusion Criteria:
- between 18-65 years old;
- able to understand the purpose of clinical research and test plan;
- In the brain MR assessment, it is judged as "normal (corresponding to age)"
Key Trial Info
Start Date :
February 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2022
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT04521439
Start Date
February 1 2020
End Date
July 30 2022
Last Update
October 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Ruijin Hospital
Shanghai, China, 200025